| # | Drug | Count |
|---|---|---|
| 0 | LENALIDOMIDE | 27 |
| 1 | POMALIDOMIDE | 18 |
| 2 | MELPHALAN HYDROCHLORIDE | 15 |
| 3 | CYCLOPHOSPHAMIDE | 13 |
| 4 | CYCLOPHOSPHAMIDE FOR INJECTION | 13 |
| 5 | CYCLOPHOSPHAMIDE INJECTION, SOLUTION | 13 |
| 6 | ADALIMUMAB | 12 |
| 7 | ADALIMUMAB-AATY | 12 |
| 8 | ADALIMUMAB-ADAZ | 12 |
| 9 | ADALIMUMAB-FKJP | 12 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | IDECABTAGENE VICLEUCEL | 5 | 0.0040 |
| 1 | ETOPOSIDE PHOSPHATE | 2 | 0.0012 |
| 2 | LISOCABTAGENE MARALEUCEL | 1 | 0.0011 |
| 3 | CILTACABTAGENE AUTOLEUCEL | 6 | 0.0009 |
| 4 | IDARUBICIN HYDROCHLORIDE | 1 | 0.0009 |
| 5 | MELPHALAN HYDROCHLORIDE | 15 | 0.0006 |
| 6 | PENICILLIN G | 1 | 0.0004 |
| 7 | PANITUMUMAB | 6 | 0.0004 |
| 8 | ERYTHROMYCIN | 7 | 0.0004 |
| 9 | DANAZOL | 1 | 0.0004 |
| # | Drug class | Count |
|---|---|---|
| 0 | Corticosteroid [EPC] | 28 |
| 1 | Thalidomide Analog [EPC] | 28 |
| 2 | Alkylating Drug [EPC] | 19 |
| 3 | Platinum-based Drug [EPC] | 16 |
| 4 | Tumor Necrosis Factor Blocker [EPC] | 13 |
| 5 | Nucleoside Metabolic Inhibitor [EPC] | 12 |
| 6 | Antirheumatic Agent [EPC] | 11 |
| 7 | Aminosalicylate [EPC] | 10 |
| 8 | Folate Analog Metabolic Inhibitor [EPC] | 10 |
| 9 | Interleukin-17A Antagonist [EPC] | 10 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Antimetabolite Immunosuppressant [EPC] | 6 | 0.0003 |
| 1 | CD33-directed Immunoconjugate [EPC] | 1 | 0.0003 |
| 2 | Interleukin-17A Antagonist [EPC] | 10 | 0.0003 |
| 3 | CD38-directed Cytolytic Antibody [EPC] | 1 | 0.0002 |
| 4 | Macrolide Antimicrobial [EPC] | 7 | 0.0001 |
| 5 | Epidermal Growth Factor Receptor Antagonist [EPC] | 6 | 0.0001 |
| 6 | Antirheumatic Agent [EPC] | 11 | 0.0001 |
| 7 | Aminosalicylate [EPC] | 10 | 0.0001 |
| 8 | Alkylating Drug [EPC] | 19 | 0.0001 |
| 9 | Dihydrofolate Reductase Inhibitor Antibacterial [EPC] | 7 | 0.0001 |